We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





KaiMi Biotech Highlights First of Its Kind Color-Changing Swabs

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: QiDix color-changing swabs (Photo courtesy of KaiMi Biotech)
Image: QiDix color-changing swabs (Photo courtesy of KaiMi Biotech)

KaiMi Biotech (Jiangsu, China) is highlighting its innovative Unow multiplexing drug tests and first-of-its-kind QiDix color-changing swabs at MEDICA 2023.

KaiMi Biotech has launched a series of breakthrough Unow multiplexing drug tests based on its proprietary user-friendly Unow technology platform. These innovative drug tests offer several unprecedented advantages over existing drug tests available in the market to meet the long unmet needs of users. The tests need only a small quantity of saliva sample (80 ml) and a short sampling time (2s) to provide user convenience. A color-appearing indicator tells users if enough saliva has been collected to give them confidence and prevent test inconsistency as a result of sampling errors.

The Unow multiplexing drug tests can be run by a single hand with fewer steps than existing commercial tests and the results can be obtained in 5-10 minutes. Integrated running buffers in the test devices eliminate direct user contact with liquid diluent and reduce potential contamination. The US FDA-approved and CE-marked tests offer excellent detection sensitivity for all the common drugs of abuse that meets the standard cutoffs for most regions around the world. The tests offer great flexibility for customization for detecting different combinations of drugs in a single device to meet the customer’s specific needs.

At MEDICA 2023, KaiMi is also presenting its flagship product, the QiDix color-changing swabs. These swabs are immobilized with a proprietary color indicator to help users ensure that enough samples have been collected. The US FDA-approved QiDix swabs are particularly useful for collecting samples for babies and kids, or patients who have challenges collecting samples by themselves. The indicator can be triggered by body fluids such as saliva, nasal secretion, sweat, tears, and urine, but not by water. The color change will not fade once triggered and the color indicators consist of only safe food-grade ingredients. A number of types of QiDix swabs are available, ranging from flocked swabs, woven swabs, and cotton swabs.

Related Links:
KaiMi Biotech

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Orienta Tsutsugamushi Test
STANDARD Q Tsutsugamushi IgM/IgG
New
Celiac Disease Test
AESKULISA tTg-A New Generation

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.